Considering investing in crispr stocks? While the best crispr stocks depend on your portfolio and investment goals, we've identified some crispr stocks that are worth keeping an eye on in the gene editing sector. Keep reading to learn more about crispr stocks and how to start investing.
We round up a selection of stocks in or related to the gene editing industry, weighting the list more heavily towards popular mid- and large-cap stocks.
| Best stock | 1-year return | Market cap | Exchange | Volume | Buy on Questrade |
|---|---|---|---|---|---|
| Crispr Therapeutics (CRSP.US) | 21.25% | $4.7 billion (USD) | NASDAQ | 1,671,782 | Buy now |
| Editas Medicine (EDIT.US) | 50.00% | $259.9 million (USD) | NASDAQ | 996,708 | Buy now |
| Regeneron Pharmaceuticals (REGN.US) | 2.52% | $73.2 billion (USD) | NASDAQ | 1,397,639 | Buy now |
| Beam Therapeutics Inc (BEAM.US) | 48.34% | $2.9 billion (USD) | NASDAQ | 1,487,265 | Buy now |
| Eli Lilly and Company (LLY.US) | 36.73% | $905.8 billion (USD) | NYSE | 3,716,234 | Buy now |
| Intellia Therapeutics (NTLA.US) | 23.47% | $1.7 billion (USD) | NASDAQ | 5,502,094 | Buy now |
| Caribou Biosciences (CRBU.US) | 79.09% | $226.1 million (USD) | NASDAQ | 1,801,746 | Buy now |
| Vertex Pharmaceuticals (VRTX.US) | -2.88% | $110.9 billion (USD) | NASDAQ | 1,219,096 | Buy now |
The gene editing industry is affected by a range of complex factors such as trade policies, regulations, and fluctuating supply and demand. So when considering crispr stocks to buy, it's important that you have access to vital information about a company's financial health, leadership team, and market positioning.
Also keep in mind that, while volatility can be ideal for day traders, long-term investors will want to look for stocks to offer steadier gains over time.
A lot of factors go into picking the best crispr stocks. Stock performance can be impacted by factors like market conditions, company decisions and global events. Plus, what may be a strong crispr stock investment for one person might not be suitable for another.
That said, we rounded up this list of popular crispr stocks in or related to the gene editing industry to help narrow down your options:
Keep in mind that this is not a "best" list or a recommendation. It highlights some crispr stocks for informational purposes only and does not indicate past or future performance or investment advice. We do not guarantee any investment performance.
We've outlined detailed company and stock performance details for each crispr stock below. Keep reading to decide if any of these companies are the right investment for you.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology.
| Closing stock price | $47.59 |
|---|---|
| Market Capitalization | $4.7 billion |
| Gross profit (TTM) | $-478,712,992 |
| Revenue (TTM) | $4.1 million |
| Earnings per share (TTM) | -$6.17 |
| 52-week stock price range | $35.38 – $78.48 |
Editas Medicine, Inc. , a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
| Closing stock price | $2.46 |
|---|---|
| Market Capitalization | $259.9 million |
| Gross profit (TTM) | $-42,267,000 |
| Profit margin | -281.59% |
| Revenue (TTM) | $38.7 million |
| Earnings per share (TTM) | -$1.14 |
| 52-week stock price range | $1.43 – $4.54 |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.
| Closing stock price | $630.30 |
|---|---|
| Market Capitalization | $73.2 billion |
| Gross profit (TTM) | $6.5 billion |
| Profit margin | 29.65% |
| Revenue (TTM) | $14.9 billion |
| Earnings per share (TTM) | $40.99 |
| 52-week stock price range | $474.60 – $820.12 |
Beam Therapeutics Inc. , a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.
| Closing stock price | $26.33 |
|---|---|
| Market Capitalization | $2.9 billion |
| Gross profit (TTM) | $-240,930,000 |
| Profit margin | -40.23% |
| Revenue (TTM) | $164 million |
| Earnings per share (TTM) | -$0.49 |
| 52-week stock price range | $15.35 – $36.44 |
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer.
| Closing stock price | $1,021.41 |
|---|---|
| Market Capitalization | $905.8 billion |
| Gross profit (TTM) | $59.8 billion |
| Profit margin | 34.99% |
| Revenue (TTM) | $72.2 billion |
| Earnings per share (TTM) | $28.85 |
| 52-week stock price range | $620.46 – $1,132.06 |
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats ("CRISPR")/CRISPR associated 9 ("Cas9") technology for genome editing.
| Closing stock price | $11.94 |
|---|---|
| Market Capitalization | $1.7 billion |
| Gross profit (TTM) | $-230,670,000 |
| Revenue (TTM) | $66.1 million |
| Earnings per share (TTM) | -$3.52 |
| 52-week stock price range | $6.83 – $28.25 |
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies.
| Closing stock price | $1.97 |
|---|---|
| Market Capitalization | $226.1 million |
| Gross profit (TTM) | $-96,320,000 |
| Revenue (TTM) | $11.2 million |
| Earnings per share (TTM) | -$1.42 |
| 52-week stock price range | $0.92 – $3.54 |
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor.
| Closing stock price | $434.31 |
|---|---|
| Market Capitalization | $110.9 billion |
| Gross profit (TTM) | $6.6 billion |
| Profit margin | 35.51% |
| Revenue (TTM) | $12.2 billion |
| Earnings per share (TTM) | $16.87 |
| 52-week stock price range | $362.50 – $507.92 |
Compare special offers, low fees and a wide range of investment options among popular trading platforms in Canada. Note that the dollar amounts in the table below are in CAD.
To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score, the better the platform—it's that simple.
Here’s what we know about the SpaceX IPO plus information on how to buy in from Canada.
We break down which companies hold Ethereum, why they’re doing it and what ETH treasuries mean for markets and investors.
Want to invest in the Euro Stoxx 50 in Canada? Explore investment platforms and popular Euro Stoxx 50 index funds.
Anthropic, which owns the AI model Claude, is expected to go public soon. Here’s what we know about the IPO and how to buy in from Canada.
New to Questrade? Check out available promotions and offer codes on now.
ChatGPT’s parent company, OpenAI, is expected to go public soon. Here’s what we know about the IPO and how to buy in from Canada.
Enjoy perks like free trades and cash back when you open a stock trading account with these online broker promotions.
NBDB stands out from other Big Bank investment apps for offering free stock & ETF trades, but there are some drawbacks. Learn more in our review.
Want to invest in amusement parks? We’ve put together a list of theme park stocks you should keep your eye on.
Want to invest in garbage collection companies? We’ve put together a list of waste management stocks to keep an eye on.
These are the best renewable energy stocks to buy now in Canada.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Whether you’re a new or experienced investor, these are the best stock trading platforms and apps in Canada.